Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients with skin alterations associated with atopic dermatitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Spirig Pharma Ltd.
• Treatments: Sertaconazole

Criteria

Inclusion Criteria:

• Informed consent

• Atopic Dermatitis Patients with SCORing Atopic Dermatitis (SCORAD) ≤ 40

• Atopic lesion localisation: arms; additional legs, neck

Exclusion Criteria:

• SCORAD > 40

• Unstable, uncontrolled medical status (e.g. active systemic or topical infection)

• Active immunosuppression or cancer

• Narcotics- or Alcohol abuse

• Participation in another clinical trial until one month prior inclusion

• Known allergies against an ingredient of the investigational medicinal product

• Different periods of grace for certain pre-treatments, e.g. topical corticosteroids, immune modulating drugs

• Pregnancy or lactation